A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer

Inclusion Criteria: * Have advanced liposarcoma or leiomyosarcoma that has metastasized (spread) * Have a pathology specimen available for centralized review * Have progressive or relapsed (reappearance of) disease, received treatment with anthracycline and/or ifosfamide before enrollment in study, and have at least one measurable tumor lesion * Have adequate bone marrow, liver and kidney function * Have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Exclusion Criteria: * Previous exposure to Yondelis i.v. formulation, ET-743 (ecteinascidin) * Cancer that has metastasized (spread) to the central nervous system * Active viral hepatitis or chronic liver disease * Unstable cardiac (heart) condition including congestive heart failure or angina pectoris (heart pain), myocardial infarction (heart attack) within 1 year before enrollment * History of another neoplastic (malignant or nonmalignant tumor) disease (except basal cell carcinoma or cervical carcinoma adequately treated), unless in remission for 5 years or more before enrollment